EVERSUN

 Kidney — Closed

EVERSUN
This study looks at the effectiveness of the chemotherapy drugs Everolimus and Sunitinib, used in sequence, in treating people with advanced renal cell carcinoma. Trial details: Participants will all receive the same treatment. This involves six-weekly cycles comprising four weeks of sunitinib 50 mg once daily followed by two weeks rest The second cycle comprises five weeks of everolimus 10 mg once daily followed by one weeks rest. The study aims to see the effectiveness of treatment by looking at survival and disease progression in patients after six months.
If you think this trial might be right for you, please ask your doctor.
Trial Title
A phase 2 trial evaluating the effect of Everolimus alternating with Sunitinib on progression-free survival in patients with advanced renal cell carcinoma.
Cancer Type
Kidney
Trial Status
Closed
Protocol Number
ANZUP 0901
Co-ordinating centre
Study Chair
Ian Davis
Recruitment Target
55 participants
Detailed Information
Participating Centres